Efficacy and safety of ofatumumab and bendamustine followed by ofatumumab maintenance in patients with relapsed indolent non-Hodgkin lymphoma after prior rituximab

被引:1
作者
Lyons, Roger M. [1 ,2 ]
Shtivelband, Mikhail [3 ]
Kingsley, Edwin [2 ,3 ]
Moezi, Mehdi [4 ]
Richards, Donald [2 ,5 ]
Sharman, Jeff [4 ,6 ]
Feng, Xiaoshu [7 ]
Cannan, Megan [7 ]
Fellague-Chebra, Rafik [8 ]
Boyd, Thomas E. [9 ,10 ]
机构
[1] Texas Oncol, San Antonio, TX 78229 USA
[2] US Oncol Res, The Woodlands, TX USA
[3] Ironwood Canc & Res Ctr, Chandler, AZ USA
[4] Comprehens Canc Ctr Nevada, Las Vegas, NC USA
[5] Tyler Canc Ctr, Tyler, TX USA
[6] Willamette Canc Ctr, Eugene, OR USA
[7] Novartis Pharmaceut, E Hanover, NJ USA
[8] Novartis Pharma SAS, Paris, France
[9] Yakima Valley Mem Hosp, Yakima, WI USA
[10] Willamette Valley Canc Inst, US Oncol Res, Eugene, OR USA
关键词
Indolent non-Hodgkin lymphoma; ofatumumab maintenance; bendamustine; clinical trial; ANTI-CD20; MONOCLONAL-ANTIBODY; PHASE-II MULTICENTER; PLUS RITUXIMAB; LOW-GRADE; B-CELL; REFRACTORY INDOLENT; 1ST-LINE TREATMENT; MANTLE CELL; THERAPY; CHOP;
D O I
10.1080/10428194.2020.1869957
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In indolent non-Hodgkin's lymphoma (iNHL), patients treated with rituximab, alone or in combination with various chemotherapeutic agents eventually relapse. This study evaluated the combination of ofatumumab and bendamustine, followed by maintenance ofatumumab in patients with relapsed iNHL with prior sensitivity to rituximab. Among the 49 patients enrolled, 24.5% achieved a complete response (CR) and 42.9% achieved a partial response (PR), with an overall response rate of 67.3% at the end of the induction therapy. Additionally, six patients with PR during induction phase achieved CR during the maintenance phase. Treatment-related adverse event was observed in 95.9% patients. The most common hematologic and biochemical abnormalities were decrease in lymphocytes (85.7%) and increase in glucose (91.8%), respectively. Overall, 42.9% progressed and 14.3% died during the study. Thus, ofatumumab in combination with bendamustine, followed by ofatumumab maintenance, was effective in the treatment of patients with iNHL with a manageable safety profile (NCT01294579).
引用
收藏
页码:1353 / 1360
页数:8
相关论文
共 37 条
[1]   Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial [J].
Ardeshna, KM ;
Smith, P ;
Norton, A ;
Hancock, BW ;
Hoskin, PJ ;
MacLennan, KA ;
Marcus, RE ;
Jelliffe, A ;
Hudson, GV ;
Linch, DC .
LANCET, 2003, 362 (9383) :516-522
[2]   High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas [J].
Bremer, K .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2002, 128 (11) :603-609
[3]   The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications [J].
Campo, Elias ;
Swerdlow, Steven H. ;
Harris, Nancy L. ;
Pileri, Stefano ;
Stein, Harald ;
Jaffe, Elaine S. .
BLOOD, 2011, 117 (19) :5019-5032
[4]  
Chao Mark P, 2013, Cancer Manag Res, V5, P251, DOI 10.2147/CMAR.S34273
[5]   Revised response criteria for malignant lymphoma [J].
Cheson, Bruce D. ;
Pfistner, Beate ;
Juweid, Malik E. ;
Gascoyne, Randy D. ;
Specht, Lena ;
Horning, Sandra J. ;
Coiffier, Bertrand ;
Fisher, Richard I. ;
Hagenbeek, Anton ;
Zucca, Emanuele ;
Rosen, Steven T. ;
Stroobants, Sigrid ;
Lister, T. Andrew ;
Hoppe, Richard T. ;
Dreyling, Martin ;
Tobinai, Kensei ;
Vose, Julie M. ;
Connors, Joseph M. ;
Federico, Massimo ;
Diehl, Volker .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (05) :579-586
[6]   Bendamustine Produces Durable Responses With an Acceptable Safety Profile in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma [J].
Cheson, Bruce D. ;
Friedberg, Jonathan W. ;
Kahl, Brad S. ;
Van der Jagt, Richard H. ;
Tremmel, Lothar .
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (06) :452-457
[7]   Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy:: 9-year follow-up [J].
Czuczman, MS ;
Weaver, R ;
Alkuzweny, B ;
Berlfein, J ;
Grillo-López, AJ .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (23) :4711-4716
[8]   Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma [J].
Czuczman, Myron S. ;
Kahanic, Stephen ;
Forero, Andres ;
Davis, Glen ;
Munteanu, Mihaela ;
Van den Neste, Eric ;
Offner, Fritz ;
Bron, Dominique ;
Quick, Donald ;
Fowler, Nathan .
ANNALS OF HEMATOLOGY, 2015, 94 (04) :633-641
[9]   Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study [J].
Czuczman, Myron S. ;
Fayad, Luis ;
Delwail, Vincent ;
Cartron, Guillaume ;
Jacobsen, Eric ;
Kuliczkowski, Kazimierz ;
Link, Brian K. ;
Pinter-Brown, Lauren ;
Radford, John ;
Hellmann, Andrzej ;
Gallop-Evans, Eve ;
DiRienzo, Christine G. ;
Goldstein, Nancy ;
Gupta, Ira ;
Jewell, Roxanne C. ;
Lin, Thomas S. ;
Lisby, Steen ;
Schultz, Martin ;
Russell, Charlotte A. ;
Hagenbeek, Anton .
BLOOD, 2012, 119 (16) :3698-3704
[10]   Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma [J].
Czuczman, Myron S. ;
Hess, Georg ;
Gadeberg, Ole V. ;
Pedersen, Lars M. ;
Goldstein, Nancy ;
Gupta, Ira ;
Jewell, Roxanne C. ;
Lin, Thomas S. ;
Lisby, Steen ;
Strange, Claus ;
Windfeld, Kristian ;
Viardot, Andreas .
BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 (04) :438-445